This is a review of the proPSMA trial, prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy.
Independent expert commentary is provided by Dr James Thompson, Urologist at St George Hospital and St Vincent’s Clinic in Sydney and Dr Geoff Schembri, a nuclear medicine physician and senior staff specialist at Royal North Shore Hospital in Sydney.
Please login below to download this issue (PDF)